CompletedPhase 2NCT00802594
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Studying African trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immtech Pharmaceuticals, Inc
- Principal Investigator
- Christian Burri, MSc, PhDSwiss Tropical & Public Health Institute
- Intervention
- DB289(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2001 – 2004
Study locations (2)
- Laboratory of Reference and Investigation, Viana, ICCT, Bairro Ingombota, Luanda Province, Angola
- Programme National de Lutte contre la Trypanosomiase, Kinshasa, Gombe, Republic of the Congo
Collaborators
Bill and Melinda Gates Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00802594 on ClinicalTrials.govOther trials for African trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07106385The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Improving Sleep Quality in Adults Without Serious Mental IllnessThe University of Hong Kong
- ACTIVE NOT RECRUITINGNCT04565769Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint InhibitorsAarhus University Hospital
- RECRUITINGNCT01778504Studying Childhood-onset Behavioral, Psychiatric, and Developmental DisordersNational Institute of Mental Health (NIMH)